<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23357">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874613</url>
  </required_header>
  <id_info>
    <org_study_id>T97/2011</org_study_id>
    <nct_id>NCT01874613</nct_id>
  </id_info>
  <brief_title>Clinical Study of FRC Implant to Treat Skull Bone Defects</brief_title>
  <acronym>Cranio-2</acronym>
  <official_title>Clinical Study of Skull Defect Reconstruction With Patient-specific Fibre-reinforced Composite Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku Clinical Biomaterials Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <authority>Finland: National Supervisory Authority for Welfare and Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioactive fibre-reinforced composite implant is used for reconstruction of skull bone
      defects and orbital floor defects.

      Functional and aesthetic outcome is assessed by patient and doctor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Development phase: Clinical trial Objectives: Assessment of functional and aesthetic outcome
      Methodology: Intervention study Sample size: 35+20+25 Main criteria for inclusion: Skull
      bone defect OR orbital floor fracture

      Investigational drug/treatment, dose and mode of administration: FRC implant Comparative
      drug(s)/placebo/treatment, dose and mode of administration:  -

      Duration of treatment:  2 years of follow-up

      Assessments:

      Clinical outcome and radiologic assesment Functional and aesthetic outcome with Visual
      Analog Scale (VAS). Pain assessment with VAS.

      Statistical methods:

      Adequate statistical methods for publishing in international peer-reviewed journals.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>2 year follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>After reconstruction, patient follow-up protocol follows to assess functional outcome, including safety.
Follow-up is done at timepoints of 1 week, 1 month, 3 months, 6 months and after that every 6 month up to 2 years post-operatively. After this the follow-up is continued yearly, if necessary.
Visual and manual assessment is done by a doctor. Lateral and PA skull rtg is obtained to assess the fixation and position of the implant.
C-reactive protein level and leukocyte level is measured to assess the possible inflammation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aesthetic outcome</measure>
    <time_frame>2 years post-operatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>After reconstruction, patient follow-up protocol follows to assess aesthetic outcome.
Follow-up is done at timepoints of 1 week, 1 month, 3 months, 6 months and after that every 6 month up to 2 years post-operatively. After this the follow-up is continued yearly, if necessary.
Visual and manual assessment is done by a doctor. Visual Analog Scale (VAS) is used by patient to assess
functional outcome
aesthetic outcome
pain Lateral and PA skull rtg is obtained to assess the fixation and position of the implant.
C-reactive protein level and leukocyte level is measured to assess the possible inflammation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Skull Bone Defect</condition>
  <condition>Craniofacial Bone</condition>
  <condition>Reconstruction</condition>
  <condition>Fibre-reinforced Composite</condition>
  <arm_group>
    <arm_group_label>Skull bone reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with skull bone defect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orbital floor defect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with orbital floor defect</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reconstruction of skull bone defect with bioactive FRC implant</intervention_name>
    <arm_group_label>Skull bone reconstruction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reconstruction of orbital floor defect with bioactive FRC implant</intervention_name>
    <arm_group_label>Orbital floor defect</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Study arm 1:

          -  patients with skull bone defect

          -  reconstruction indications fullfilled

        Study arm 2:

          -  patients with orbital floor defect

          -  reconstruction indication fullfilled

        Exclusion Criteria:

          -  if informed consent cannot be obtained
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kalle J Aitasalo, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kalle J Aitasalo, Professor</last_name>
    <phone>+358 2 313000</phone>
    <email>kalle.aitasalo@tyks.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Otorhinolaryngology</name>
      <address>
        <city>Turku</city>
        <state>N/A = Not Applicable</state>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalle J Aitasalo, PhD</last_name>
      <phone>35823130000</phone>
      <email>kalle.aitasalo@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Jaakko Piitulainen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jami Rekola, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>November 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Craniofacial bone reconstruction</keyword>
  <keyword>fibre-reinforced composite</keyword>
  <keyword>bioactive glass</keyword>
  <keyword>craniotomy</keyword>
  <keyword>skull bone defect</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
